Dr. Lal PathLabs sets sights on a substantial 13-15% increase in revenue by FY27, with strategies centered around expanding their network and prioritizing digital advancements.

Dr. Lal PathLabs announced their Q4 results for FY25-26, proposing a dividend of INR 4 per share. The company also expanded its reach with the acquisition of a diagnostic center and the establishment of a new subsidiary in Dubai. Additionally, some directors were reappointed.

Dr. Lal PathLabs Q4 earnings report shows a decline in profit by 14% year-on-year, from ₹155 crore to ₹131 crore. Despite the drop, revenue increased by 16%, reaching ₹703 crore. However, the margin narrowed to 26.6%.

Dr. Lal PathLabs has taken over Shahbazker's Diagnostic Centre, making it a fully owned entity within their diagnostic network, thereby expanding their reach in the healthcare industry.

There's been a noticeable increase in trading volume for companies like Dr Lal Pathlabs, Torrent Power, Tube Investments, Godrej Consumer, and HCL Tech, according to recent data. However, the report doesn't provide comprehensive analysis and wasn't penned by Business Standard journalists.